{
  "url": "https://openlegislation.uk/eu-decision-2006-430/division-3/2/6",
  "json_url": "https://openlegislation.uk/eu-decision-2006-430/division-3/2/6.json",
  "legislation": "eudn/2006/430",
  "legislation_title": "Commission Decision of 25 August 2005 declaring a concentration compatible with the common market and the functioning of the EEA Agreement (Case COMP/M.3687 — Johnson & Johnson/Guidant) (notified under document number C(2005) 3230) (Only the English text is authentic) (Text with EEA relevance) (2006/430/EC)",
  "legislation_url": "https://openlegislation.uk/eu-decision-2006-430",
  "path": "division/3/2/6",
  "kind": "division",
  "number": "(28)",
  "heading": null,
  "text": "There are three main players in the carotid stent market: J & J, Guidant and Boston Scientific. Together they account for 83 to 96 % of the market. The concentration will either reinforce the leadership of J & J or Guidant (in Austria, Finland, the Netherlands, Portugal and Spain) or combine the second and third player to create a new market leader (Belgium, Germany and Italy).",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudn/2006/430/division/3/2/6",
    "retrieved_at": "2026-11-01T15:17:33.972712+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}